Whereas immune checkpoint inhibitors have revolutionized cancer treatment across many tumor indications and demonstrated the usefulness of interjecting the PD-1:PD-L1 axis, only a fraction of patients benefit from these drugs and develop durable clinical responses (7, 8). The gene discussed is CD274; the disease is cancer.